Financial News Feed

Stronger Sell Today ACHN ranks #3891 as SELL CANDIDATE #3891 Weaker Sell

Achillion Pharmaceuticals stock forecast

ACHN stock forecast

Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

Read more

Top Health Care Stocks Top Health Care Stocks JNJ 0 43 JNJ 0 43 PFE 0 74 PFE 0 74 ABT 0 13 ABT 0 13 MRK 0 76 MRK 0 76 AMGN FlatAMGN Flat Most health care giants were lower in Friday s pre bell trade Most health care giants were lower in Friday s pre bell trade Stocks...

Read more

ACHN and CRAY among premarket gainers
01:20pm, Friday, 17'th May 2019
No summary available....

Read more

- ACH-4471 increased hemoglobin and nearly eliminated the need for transfusions in patients with PNH being treated with C5 inhibitor, eculizumab - BLUE BELL, Pa., May 17, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN ), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today reported interim data from a Phase 2 paroxysmal nocturnal hemoglobinuria (PNH) trial assessing the safety and effectiveness of its oral small molecule factor D inhibitor ACH-4471 in combination with intravenous eculizumab at The New Era of Aplastic Anemia and PNH Meeting in Naples, Italy. "Anemia is a persistent problem in the majority of patients with PNH treated with standard and even high doses of eculizumab. These interim data are encouraging and demonstrate that ACH-4471, when used in combination with a C5 inhibitor, such as eculizumab, has the potential to improve anemia, decrease transfusions and lead to improvement in important clinical parameters of hemolysis as well as quality of life measurements for patients with this devastating condition," stated Joseph Truitt, Chief Executive Officer at Achillion....

Read more

No summary available....

Read more

No summary available....

Read more

The clinical-stage biotech didn't have any revenue in the first quarter. But it made progress in several key areas....

Read more

Achillion Pharmaceuticals EPS in-line
10:20am, Thursday, 09'th May 2019
Achillion Pharmaceuticals (ACHN): Q1 GAAP EPS of -$0.14 in-line. Cash, cash equivalents and marketable securities of $254.1M Press Release...

Read more

ANET, CTSH and FTNT among premarket losers
01:12pm, Friday, 03'rd May 2019
No summary available....

Read more

No summary available....

Read more

Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

Read more

Achillion (ACHN) achieves enrollment target in two mid-stage studies evaluating its lead candidate, ACH-4471 in C3G, a devastating disease affecting the kidney....

Read more

Reaching a key clinical study milestone provided a nice boost to the biotech stock....

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank